Itacitinib for the prevention of IEC therapy–associated CRS: results from the 2-part phase 2 INCB 39110-211 study

Journal:

Blood

Published:

2025-07-24

DOI:

10.1182/blood.2024026586

Affiliations:

13

Authors:

14

Go to article

Institutions	Authors	Share
Incyte, United States of America (USA)	3.000000	0.21
Massachusetts General Hospital Cancer Center, United States of America (USA)	1.000000	0.07
Oregon Health and Science University (OHSU), United States of America (USA)	1.000000	0.07
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)	1.000000	0.07
H. Lee Moffitt Cancer Center & Research Institute, United States of America (USA)	1.000000	0.07
Medical College of Wisconsin (MCW), United States of America (USA)	1.000000	0.07
Abramson Cancer Center, Penn, United States of America (USA)	1.000000	0.07
University of Miami Health System (UHealth), United States of America (USA)	1.000000	0.07
Columbia University Irving Medical Center (CUIMC), CU, United States of America (USA)	1.000000	0.07
Incyte Biosciences International Sàrl, Switzerland	1.000000	0.07
Washington University in St. Louis (WUSTL), United States of America (USA)	1.000000	0.07
University of Cincinnati (UC), United States of America (USA)	0.500000	0.04
Cincinnati Children's Hospital Medical Center (CCHMC), United States of America (USA)	0.500000	0.04

Interested in Oncology and Carcinogenesis?